News

The Phase 2 trial will investigate whether VT-122 in combination with Nexavar increases ‘Clinical Benefit Response,’ which is a composite measurement of pain, performance status, and lean body

With the initiation of the trial, Emergent BioSolutions has dosed first patient in the trial. According to the company, the Phase I trial is designed to investigate the

Earlier, Pain Therapeutics and King have entered into a strategic alliance to develop and commercialize Remoxy and other abuse-resistant opioid painkillers, in 2005. Remoxy, developed by Pain Therapeutics,

Glucotim LA of Centaur Pharma is an original research formulation of Timolol Long Acting developed by Senju. Centaur Pharma has introduced the vial for the first time in

As per the terms of the modification Elan will pay $9m to Transition at the time of signing the modified agreement and will also pay $11m upon the

Motavizumab is an investigational monoclonal antibody that was being considered to help prevent RSV disease. AstraZeneca has requested withdrawal of the biological license application (BLA) pending at the

The acquisition adds the APEX information management system – enabled with an advanced speech recognition and speech understanding engine – to Accentus’ technology base, driving significant cost savings

The study enrolled patients with previously untreated CUP, were randomized into one of two treatment arms: Belinostat + carboplatin and paclitaxel (BelCaP), or carboplatin and paclitaxel (CaP). The

He previously served as a member of the Cephalon executive management team in the roles of chief operating officer and chief financial officer. Additionally, for the last seven